Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease
Sokrates Stein, … , Maaike H. Oosterveer, Kristina Schoonjans
Sokrates Stein, … , Maaike H. Oosterveer, Kristina Schoonjans
Published January 17, 2017
Citation Information: J Clin Invest. 2017;127(2):583-592. https://doi.org/10.1172/JCI85499.
View: Text | PDF
Research Article Hepatology Metabolism

Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease

  • Text
  • PDF
Abstract

Hepatic steatosis is caused by metabolic imbalances that could be explained in part by an increase in de novo lipogenesis that results from increased sterol element binding protein 1 (SREBP-1) activity. The nuclear receptor liver receptor homolog 1 (LRH-1) is an important regulator of intermediary metabolism in the liver, but its role in regulating lipogenesis is not well understood. Here, we have assessed the contribution of LRH-1 SUMOylation to the development of nonalcoholic fatty liver disease (NAFLD). Mice expressing a SUMOylation-defective mutant of LRH-1 (LRH-1 K289R mice) developed NAFLD and early signs of nonalcoholic steatohepatitis (NASH) when challenged with a lipogenic, high-fat, high-sucrose diet. Moreover, we observed that the LRH-1 K289R mutation induced the expression of oxysterol binding protein-like 3 (OSBPL3), enhanced SREBP-1 processing, and promoted de novo lipogenesis. Mechanistically, we demonstrated that ectopic expression of OSBPL3 facilitates SREBP-1 processing in WT mice, while silencing hepatic Osbpl3 reverses the lipogenic phenotype of LRH-1 K289R mice. These findings suggest that compromised SUMOylation of LRH-1 promotes the development of NAFLD under lipogenic conditions through regulation of OSBPL3.

Authors

Sokrates Stein, Vera Lemos, Pan Xu, Hadrien Demagny, Xu Wang, Dongryeol Ryu, Veronica Jimenez, Fatima Bosch, Thomas F. Lüscher, Maaike H. Oosterveer, Kristina Schoonjans

×

Figure 2

Osbpl3 is a direct LRH-1 target gene and overexpressed in LRH-1 K289R mice.

Options: View larger image (or click on image) Download as PowerPoint

Osbpl3 is a direct LRH-1 target gene and overexpressed in LRH-1 K289R m...
(A) Heat map showing the hepatic expression of oxysterol-binding protein family members in WT and K289R mice. Normalized expression values are in log2 scale. (B and C) Expression of Osbpl3 mRNA in hepatic lysates of fasted and refed WT and K289R mice (B) and the fold change between the genotypes (C). n = 4 per fasted, 2-hour–, or 12-hour–refed groups, and n = 5 per 6-hour–refed groups. (D) Expression levels of OSBPL3 protein in hepatic lysates of fasted and refed WT and K289R mice. (E) Schematic showing the genomic area containing the Osbpl3 gene and the sites used for ChIP-qPCR experiments (mouse genome assembly mm10). (F and G) Binding of LRH-1 to the different Osbpl3 promoter sites assessed by ChIP analysis using genomic DNA from fasted WT (F) and refed WT livers (G). n = 5 WT fasted, n = 5 WT refed. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, §P = 2 × 10–7 relative to WT, as determined by unpaired Student’s t test (A), or 1-way (C) or 2-way (B, F, G) ANOVA with Bonferroni post-hoc test. TSS, transcription start site.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts